Men with total testosterone below 300 ng/dL have 2.4 times higher cardiovascular mortality compared to men with levels above 600 ng/dL, according to a systematic review and meta-analysis published in the Journal of Clinical Endocrinology & Metabolism (Araujo AB et al., 2011). This critical insight underscores the link between low testosterone and adverse health outcomes, challenging historical narratives that sometimes overstated TRT risks. In a significant move, the U.S. Food and Drug Administration (FDA) in February 2025 removed the boxed cardiovascular warning from all testosterone product labels, reflecting evolving evidence and the findings of large-scale clinical trials that demonstrate the cardiovascular safety of appropriately monitored testosterone replacement therapy.

Last Updated: APRIL 2024

The Shifting Landscape of TRT and Cardiovascular Health

For years, the medical community, and consequently the public, held reservations about testosterone replacement therapy (TRT) and its potential impact on cardiovascular health. These concerns were often fueled by observational studies or studies with methodological limitations, sometimes failing to differentiate between men with genuine hypogonadism receiving carefully managed therapy and those using supraphysiological doses without medical oversight. The traditional diagnostic threshold for hypogonadism, often cited around 264-300 ng/dL, has also been a point of contention. This lower bound was originally calibrated from a 1970s population that included sick and elderly men, potentially misclassifying many symptomatic men with “normal” but suboptimal testosterone levels as ineligible for treatment. A pro-health autonomy stance emphasizes that symptomology combined with consistently low-normal levels warrants clinical consideration for treatment, not arbitrary gatekeeping based on outdated reference ranges.

The paradigm has now fundamentally shifted, largely thanks to rigorous research like the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) trial.

The TRAVERSE Trial: A Landmark for Cardiovascular Safety

The TRAVERSE trial (Lincoff AM et al., 2023, New England Journal of Medicine) was a pivotal, placebo-controlled, randomized clinical trial designed specifically to assess the cardiovascular safety of TRT. This large-scale study enrolled over 5,200 middle-aged and older men with hypogonadism and pre-existing or increased risk for cardiovascular disease. Participants received either a testosterone gel or placebo and were followed for a median of 33 months.

The primary endpoint of the TRAVERSE trial was the incidence of major adverse cardiovascular events (MACE), defined as nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. The results were clear: TRT did not increase the risk of MACE compared to placebo.

“Testosterone replacement therapy in men with hypogonadism and a history of or high risk for cardiovascular disease was not associated with a greater incidence of major adverse cardiovascular events than placebo,” the TRAVERSE trial authors concluded. This finding provides robust evidence supporting the cardiovascular safety of TRT when administered and monitored appropriately, particularly with physiologic dosing that aims to restore testosterone levels to the normal range of 350-750 ng/dL.

Core Principles for Heart-Healthy TRT

Optimizing cardiovascular safety on TRT involves a multi-faceted approach, focusing on physiologic dosing, careful monitoring of key biomarkers, and proactive management of potential side effects.

Physiologic Dosing and Administration

The goal of TRT is to restore testosterone levels to a healthy, physiologic range, typically 350–750 ng/dL, mimicking the natural rhythm as closely as possible. This is achieved through consistent and controlled administration.

Testosterone Cypionate or Enanthate: These long-acting esters are common. Dosing typically ranges from 100–200mg testosterone cypionate or enanthate per week, administered via intramuscular or subcutaneous injection. Frequent injections (e.g., 50–100mg twice weekly or 30–60mg every 3.5 days) can help maintain more stable serum testosterone levels, avoiding supraphysiologic peaks and subsequent troughs. Stable levels minimize fluctuations in estradiol (E2) and reduce the risk of erythrocytosis (high hematocrit).

Hematocrit Management

Erythrocytosis, or an elevated red blood cell count leading to increased hematocrit, is a known potential side effect of TRT. High hematocrit (above 52%) can increase blood viscosity, potentially elevating the risk of thrombotic events such as stroke or deep vein thrombosis.

Monitoring: Regular monitoring of complete blood count (CBC) is crucial, typically at 3, 6, and 12 months, then annually.
Mitigation Strategies:
- Dose Adjustment: Reducing the testosterone dose (e.g., from 200mg/week to 150mg/week) or increasing injection frequency (e.g., from weekly to twice weekly) can often resolve mild erythrocytosis.
- Hydration: Maintaining adequate hydration is fundamental.
- Smoking Cessation: Smoking can independently raise hematocrit.
- Phlebotomy: For persistent or significantly elevated hematocrit (e.g., above 54%), therapeutic phlebotomy (blood donation) may be necessary, often done in 450–500mL increments. Phlebotomy should be considered a last resort after optimizing dosing protocols.

Lipid Profile and Dyslipidemia

Testosterone therapy can impact lipid profiles, with some studies showing a potential decrease in high-density lipoprotein (HDL) cholesterol and mixed effects on low-density lipoprotein (LDL) and triglycerides. While the overall clinical significance of these changes for cardiovascular risk on physiologic TRT is debated and often small, proactive management of dyslipidemia is essential.

Monitoring: Regular lipid panels (total cholesterol, HDL, LDL, triglycerides) should be performed at baseline and annually. Consider advanced lipid testing, including lipoprotein(a) [Lp(a)], a potent independent risk factor for ASCVD, especially with the insights from the 2026 Dyslipidemia Guidelines.
Management:
- Lifestyle: Emphasize diet, exercise, and weight management.
- Pharmacology: If dyslipidemia persists, statins or other lipid-lowering agents may be indicated, guided by updated risk stratification tools like the PREVENT risk equations and coronary artery calcium (CAC) scoring as per the latest dyslipidemia guidelines.
- Oral Testosterone: Oral testosterone formulations, particularly alkylated forms, are more commonly associated with adverse lipid changes and hepatic strain, making injectables (cypionate, enanthate) or transdermals preferred for long-term TRT.

Blood Pressure

TRT can lead to minor increases in blood pressure in some individuals, though this effect is generally modest and not universal. Uncontrolled hypertension is a significant cardiovascular risk factor.

Monitoring: Blood pressure should be monitored at every clinical visit.
Management:
- Lifestyle: Regular exercise, a DASH-style diet, and sodium restriction.
- Pharmacology: If blood pressure remains elevated, anti-hypertensive medications should be prescribed and managed to achieve target blood pressure (e.g., below 130/80 mmHg).

Estrogen Balance: E2, HCG, and Aromatase Inhibitors

Estradiol (E2) is an essential hormone in men, derived from testosterone via the aromatase enzyme. While supraphysiologic E2 levels can lead to side effects like gynecomastia, proper E2 levels are crucial for bone density, libido, mood, and cardiovascular health. Over-suppression of E2 can be detrimental, potentially increasing cardiovascular risk, reducing bone mineral density, and negatively impacting lipid profiles.

Monitoring: E2 levels should be monitored (sensitive estradiol assay), aiming for a range of 20–40 pg/mL on TRT.
HCG (Human Chorionic Gonadotropin): Often used alongside testosterone to maintain testicular function, preserve fertility, and contribute to endogenous testosterone and E2 production. Dosing typically ranges from 500–1000 IU HCG per week, split into 2-3 injections. HCG can elevate E2 by increasing endogenous testosterone production, which then aromatizes.
Anastrozole (Aromatase Inhibitor): AIs like anastrozole should be used judiciously and only when clinically indicated by persistently high E2 levels with symptoms (e.g., gynecomastia, significant water retention, mood swings) despite optimized testosterone dosing and administration. Over-reliance on AIs to achieve arbitrarily low E2 levels is generally discouraged due to the risks associated with E2 deficiency. Typical anastrozole dosing, if truly needed, might be 0.25–0.5mg once or twice per week.
Enclomiphene: While not a primary TRT agent, enclomiphene is a selective estrogen receptor modulator (SERM) that stimulates endogenous testosterone production by blocking

Heart-Healthy TRT: Optimizing Cardiovascular Safety